If your appetite suppression is so severe that you cannot eat enough to meet basic nutritional needs, discuss dose adjustment with your provider rather than trying to chemically override the medication
Online consultation From the comfort of your home, no in-person appointments needed
Cancel anytime
Tirzepatide for the treatment of adults with Type 2 diabetes: An endocrine perspective, National Library of Medicine (2022) Wegovy (semaglutide): a new weight loss drug for chronic weight management, National Library of Medicine (2022) Tirzepatide versus semaglutide for weight loss in patients with Type 2 diabetes mellitus: A value for money analysis, National Library of Medicine (2023) Wegovy (semaglutide): a new weight loss drug for chronic weight management, Journal of Investigative Medicine (2021) Mounjorno prescribing information, FDA (2022) Fast Track Status, FDA (2018) Priority Review, FDA (2018) FDA approves novel, dual-targeted treatment for type 2 diabetes, FDA (2022) FDA approves new medication for chronic weight management, FDA (2023) FDA approves Lillys Zepbound (tirzepatide) for chronic weight management, a powerful new option for the treatment of obesity or overweight with weight-related medical problems, Eli Lilly & Co
You may find significant savings compared to local pharmacy prices
Starting a new medication during active disease makes it harder to distinguish medication effects from disease activity and could potentially complicate flare management
